Souhaitez-vous accéder aux communiqués récents ?

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell...

First-in-human healthy volunteers trial showed SYX-5219 was safe and well toleratedSystemic immunomodulation of type 2 inflammation demonstrated with reduction in serum CCL17/TARC Phase 1b trial in...

Anaveon appoints Thomas P. Mathers as Chair of the Board of Directors.

Alira Health, in partnership with the Autoimmune Neurology Alliance (AiNA), today announced the launch of the AXIS Registry.

Study Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in...

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead program afimetoran, a potential...

Candidate has potential to be a first-in-class treatment offering biologic-like disease control from an oral small moleculeRegulatory submission preparation and entry into the clinic is expected in H1...

Oxford, UK and Boston, MA – March 26, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and...

Anaveon, a late-stage biotech company, appoints Thaminda Ramanayake as its new Chief Executive Officer.

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated...